Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Citations Over TimeTop 25% of 2023 papers
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is capable of large-scale transmission and has caused the coronavirus disease 2019 (COVID-19) pandemic. Patients with COVID-19 may experience persistent long-term health issues, known as long COVID. Both acute SARS-CoV-2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood-derived products are important strategies to combat the serious damage caused by COVID-19. Since the emergence of COVID-19, various blood-derived products that target or do not target SARS-CoV-2 have been investigated for therapeutic applications. SARS-CoV-2-targeting blood-derived products, including COVID-19 convalescent plasma, COVID-19 hyperimmune globulin, and recombinant anti-SARS-CoV-2 neutralizing immunoglobulin G, are virus-targeting and can provide immediate control of viral infection in the short term. Non-SARS-CoV-2-targeting blood-derived products, including intravenous immunoglobulin and human serum albumin exhibit anti-inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS-CoV-2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood-derived product therapies for COVID-19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.
Related Papers
- → Why will it never be known if convalescent plasma is effective for COVID-19(2020)15 cited
- LibGuides: Pandemics and COVID-19: Novel coronavirus(2020)
- → СТРУКТУРНО-КОМПОЗИЦІЙНІ ОСОБЛИВОСТІ ДИСКУРСИВНОГО РОЗГОРТАННЯ НАРАТИВУ “CORONAVIRUS PANDEMIC” (НА МАТЕРІАЛІ ІНФОРМАЦІЙНОГО ПОРТАЛУ BBC NEWS)(2021)
- → Investigation of SARS-CoV-2 RNAemia in the convalescent plasma of COVID-19 patients(2022)